Stanley Laman Group Ltd. Acquires 22,229 Shares of Lantheus Holdings, Inc. $LNTH

Stanley Laman Group Ltd. raised its holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 38.7% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 79,686 shares of the medical equipment provider’s stock after acquiring an additional 22,229 shares during the quarter. Stanley Laman Group Ltd. owned about 0.12% of Lantheus worth $4,087,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Elevation Point Wealth Partners LLC acquired a new position in shares of Lantheus in the 2nd quarter valued at $26,000. Osterweis Capital Management Inc. bought a new stake in Lantheus in the second quarter valued at about $36,000. Quarry LP lifted its stake in Lantheus by 2,350.0% in the first quarter. Quarry LP now owns 490 shares of the medical equipment provider’s stock valued at $48,000 after buying an additional 470 shares during the period. EverSource Wealth Advisors LLC lifted its stake in Lantheus by 190.2% in the second quarter. EverSource Wealth Advisors LLC now owns 1,065 shares of the medical equipment provider’s stock valued at $87,000 after buying an additional 698 shares during the period. Finally, EMC Capital Management acquired a new position in shares of Lantheus during the 2nd quarter worth about $93,000. Institutional investors and hedge funds own 99.06% of the company’s stock.

Analyst Ratings Changes

A number of brokerages recently weighed in on LNTH. TD Cowen cut their price target on shares of Lantheus from $95.00 to $80.00 and set a “buy” rating on the stock in a research report on Monday, September 15th. Mizuho boosted their price objective on shares of Lantheus from $60.00 to $72.00 and gave the company an “outperform” rating in a report on Wednesday, December 17th. Truist Financial increased their target price on shares of Lantheus from $80.00 to $82.00 and gave the stock a “buy” rating in a report on Thursday, December 18th. Weiss Ratings cut shares of Lantheus from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Saturday, October 25th. Finally, B. Riley decreased their price target on shares of Lantheus from $109.00 to $84.00 and set a “buy” rating for the company in a report on Tuesday, September 16th. Five research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Lantheus currently has a consensus rating of “Moderate Buy” and an average target price of $78.00.

Lantheus Stock Performance

Shares of LNTH stock opened at $67.27 on Monday. The company has a debt-to-equity ratio of 0.51, a quick ratio of 2.49 and a current ratio of 2.67. Lantheus Holdings, Inc. has a 52 week low of $47.25 and a 52 week high of $111.29. The company’s 50 day moving average price is $59.97 and its two-hundred day moving average price is $61.69. The company has a market capitalization of $4.46 billion, a P/E ratio of 28.26 and a beta of -0.11.

Lantheus (NASDAQ:LNTH) last released its quarterly earnings results on Tuesday, May 17th. The medical equipment provider reported $0.05 earnings per share for the quarter. Lantheus had a net margin of 10.99% and a return on equity of 30.88%. The company had revenue of $92.51 million during the quarter. On average, analysts expect that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current fiscal year.

Lantheus Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.